Neurol Ther (2022) 11:759–762 https://doi.org/10.1007/s40120-022-00346-8 CORRECTION Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab Anne H. Cross . Silvia Delgado . Mario Habek . Maria Davydovskaya . Brian J. Ward . Bruce A. C. Cree . Natalia Totolyan . Ratnakar Pingili . Linda Mancione . Xixi Hu . Roseanne Sullivan . Wendy Su . Ronald Zielman . Ayan Das Gupta . Xavier Montalban . Kevin Winthrop Published online: May 3, 2022  The Author(s) 2022 Correction to: https://doi.org/10.1007/s40120- literature. These changes did not impact upon 022-00341-z the conclusions of the article. The specific corrections made are provided In the published article a few errors have been below: identified, these have subsequently been recti- Abstract fied. Alterations were also made to sentences and reference numbering to improve the clarity • The value of 14.3% has been amended to of sentences and better reflect the published 14.4% as the calculated value was 14.38% * 14.4%. Introduction: The original article can be found online at https://doi. org/10.1007/s40120-022-00341-z. • The value 9.7% was replaced with 15.5%, A. H. Cross (&) of Neurology, University of California San Department of Neurology, Washington University, Francisco, San Francisco, CA, USA St. Louis, MO, USA e-mail: crossa@wustl.edu N. Totolyan First Saint Petersburg State Medical University, St. S. Delgado Petersburg, Russia University of Miami Miller School of Medicine, Miami, FL, USA R. Pingili  L. Mancione  X. Hu  R. Sullivan  W. Su Novartis Pharmaceuticals Corporation, East M. Habek Hanover, NJ, USA University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia R. Zielman Novartis Pharma B.V., Amsterdam, The Netherlands M. Davydovskaya Moscow State Public Healthcare InsCity Clinical A. D. Gupta Hospital 24, Moscow, Russia Novartis Healthcare Private Limited, Hyderabad, India B. J. Ward Infectious Diseases Division, Research Institute of X. Montalban the McGill University Health Centre, Montreal, QC, Department of Neurology-Neuroimmunology, Canada Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, B. A. C. Cree Spain UCSF Weill Institute for Neurosciences, Department 760 Neurol Ther (2022) 11:759–762 Open-label ALITHIOS study Post-marketing reports Overall ALITHIOS patientsa Total patient years (N = 1703) (Years = 4,713) Patients with any COVID-19 Patients with any COVID-19 (N = 245) (N = 93) Confirmed Suspected Confirmed Suspected COVID-19 COVID-19 COVID-19 COVID-19 (N = 210) (N = 35) (N = 90) (N = 3) Serious cases Serious cases Serious cases (n = 23) (n = 1) (n = 10) Non-serious cases Non-serious cases Non-serious cases (n = 187) (n = 34) (n = 80) Fig. 1 Patient designation in the open-label ALITHIOS APOLITOS (n = 57), APLIOS (n = 279), and ASCLE- study and post-marketing setting. a Patients in the open- PIOS I/II (n = 1367) studies label ALITHIOS study (N = 1703) rolled-over from the and the value 1.6% was replaced with 1.97% treated with DMTs. This value refers to to align with the value from cited reference hospitalization rate for natalizumab-treated number 9 (Prosperini L, et al. 2021). MS patients. This aligns with data taken from reference number 12. (Simpson-Yap S, Results: et al.). • The value 69.6% was replaced with accurate • The statement ‘‘Earlier studies found a value 69.8%. higher risk of serious infections in patients with low IgG/IgM levels taking ocrelizumab’’ Discussion: has been modified to ‘‘Earlier studies found • Value 1.6% was altered to 1.4% which is an increased risk of serious infections in reported as the minimum value for mortality patients with low IgG levels taking ocre- in multiple sclerosis (MS) patients treated lizumab’’, taken from the newly added refer- with disease modifying therapies (DMTs). ence number 36 Hauser SL, et al. This value refers to mortality rate for natal- Figure 1: izumab-treated MS patients. This aligns with data taken from reference number 12 (Simp- • The number of serious cases and non-serious son-Yap S, et al.). cases in the post-marketing reports section • Value 21.5% was replaced with 20.9% as a were corrected to Serious cases (n = 10) and maximum range value for hospitalization Non-serious cases (n = 80). rate specific to general MS population. This Figure 2: aligns with data taken from reference num- ber 12. (Simpson-Yap S, et al.). • The date listed for when the WHO declared a • The value 13.3% was changed to 11.5% as a global pandemic was incorrect. This has minimum range value from the cited refer- been updated MARCH 11, 2020. ences for hospitalization rate in MS patients References K. Winthrop • Reference 36 replaced with new reference: School of Public Health at Oregon Health and Hauser SL, Kappos L, Montalban X, et al. Science University, Portland, OR, USA Safety of Ocrelizumab in Patients With Neurol Ther (2022) 11:759–762 761 COVID-19 cases worldwide from WHO dashboard 1st SARS-CoV-2 vaccines available Number of confirmed cases Dec-2020 6,000,000 5,000,000 1st case of Delta variant per week (n) 4,000,000 Oct-2020a WHO reports 3,000,000 cluster of cases of pneumonia in WHO declared 2,000,000 Wuhan, China global pandemic Dec-31-2019 Mar-11-2020 1,000,000 0 Dec-1-19 Mar-1-20 Jun-1-20 Sep-1-20 Dec-1-20 Mar-1-21 Jun-1-21 Sep-1-21 COVID-19 cases in the ALITHIOS study (N=245) Data cutoff date Sep-25-2021 Life-threatening Severe Severity grade Moderate Mild Missingb Dec-1-19 Mar-1-20 Jun-1-20 Sep-1-20 Dec-1-20 Mar-1-21 Jun-1-21 Sep-1-21 Partially Vaccinated Fully Vaccinated Unvaccinated/Unspecified Fig. 2 COVID-19 cases over time in the open-label ongoing study, and the data are subject to change. ALITHIOS study by severity and vaccine status. aFirst case COVID-19, coronavirus disease; SARS-CoV-2, severe of Omicron variant reported after data cut-off: November acute respiratory syndrome coronavirus-2; WHO, World 24, 2021. bSeverity grade for one patient was not yet Health Organization reported at the time of data cut-off, as ALITHIOS is an Relapsing and Primary Progressive Multiple • Reference 42 replaced with new reference: Sclerosis Neurology. 2021 Oct 19; 97(16): Apostolidis SA, Kakara M, Painter MM, et al. e1546–e1559. https://doi.org/10.1212/WNL. Cellular and humoral immune responses 0000000000012700. following SARS-CoV-2 mRNA vaccination • Reference 37 replaced with former #36: in patients with multiple sclerosis on anti- Jasinska E, Habek M, Wynn D, Dunphy S, CD20 therapy. Nat Med. Mancione L, Rennie N, Su W, Zielman R, 2021;27(11):1990–2001. https://doi.org/10. Delgado S. Impact of ofatumumab on 1038/s41591-021-01507-2. immune responses post-vaccination in RMS The original article has been corrected. patients: ALITHIOS vaccination substudy design. In: Presented at 7th Congress of the European Academy of Neurology, (Virtual); June 19–22, 2021, OPR-207. 762 Neurol Ther (2022) 11:759–762 Open Access. This article is licensed under a included in the article’s Creative Commons Creative Commons Attribution-NonCommer- licence, unless indicated otherwise in a credit cial 4.0 International License, which permits line to the material. If material is not included any non-commercial use, sharing, adaptation, in the article’s Creative Commons licence and distribution and reproduction in any medium your intended use is not permitted by statutory or format, as long as you give appropriate credit regulation or exceeds the permitted use, you to the original author(s) and the source, provide will need to obtain permission directly from the a link to the Creative Commons licence, and copyright holder. To view a copy of this licence, indicate if changes were made. The images or visit http://creativecommons.org/licenses/by- other third party material in this article are nc/4.0/.